Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.4633 -0.0067 (-1.43%)
Streaming Delayed Price Updated: 2:45 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain. 
Via The Motley Fool
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
From bluebird bio, Inc. and Resilience
Via Business Wire
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
Neither healthcare stock has performed well so far this year. 
Via The Motley Fool
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE)... 
Via Benzinga
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
From bluebird bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE: 
Via Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?
With safety concerns allayed, the company is ready to restart clinical trials of key therapies. 
Via The Motley Fool
Exposures Product Safety
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
From bluebird bio, Inc.
Via Business Wire
Bluebird bio Can Restart Halted Clinical Trials
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia. 
Via The Motley Fool
Exposures Product Safety
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio Pops As FDA Allows In-Human Gene Therapy Testing To Resume
The FDA removed a hold barring Bluebird Bio from testing its blood-disease gene therapies in people on Monday, and BLUE stock surged. 
Via Investor's Business Daily
Exposures Product Safety
FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia
The FDA has lifted the clinical hold on Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of Bluebird Bio Inc's (NASDAQ: BLUE) LentiGlobin for sickle cell... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
From bluebird bio
Via Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Is bluebird bio a Buy for Summer 2021?
With the stock down 54% over the past year, will investors be catching a falling knife if they buy now? 
Via The Motley Fool
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s... 
Via Benzinga
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
From bluebird bio, Inc.
Via Business Wire
NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc
San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc. 
Via SBWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.